Claims:

1. A pharmaceutical composition for the oral administration of an active agent having low water solubility, wherein
a) the active agent is dispersed in an aqueous formulation base; and
b) the solubilizing agent is suitable for the formation of an aqueous dispersion of nano-particles;
which is characterized in that the solubilizing agent is a pharmaceutically acceptable polymer which is resistant to gastric juices and soluble in intestinal juices.

2. A pharmaceutical composition according to claim 1, wherein the polymer, which is resistant to gastric juices and soluble in intestinal juices is a copolymer from monomers selected from the group consisting of methacrylic acid, methacrylic acid esters, acrylic acid and acrylic acid esters.

3. A pharmaceutical composition according to claim 1, wherein the polymer, which is resistant to gastric juices and soluble in intestinal juices is a pharmaceutically acceptable cellulose derivative selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropylmethylcellulose-phthalate (HPMCP), celluloseacetate-phthalate (CAP), and celluloseacetatetrimellitate (CAT).

4. A pharmaceutical composition according to claim 2, wherein the polymer is a 1:1- up to 1:2-copolymer from monomers selected from the group consisting of methacrylic acid and methacrylic acid lower alkyl esters.

5. A pharmaceutical composition according to claim 4, wherein the copolymer is a 1:1- up to 1:2-copolymer of methacrylic acid and methacrylic acid methyl ester.

6. A pharmaceutical composition according to claim 2, wherein the copolymer is a 1:1-copolymer of methacrylic acid and acrylic acid ethyl ester.

7. A pharmaceutical composition according to claim 1, wherein the solubilizing agent is suitable for the formation of nanospheres.

8. A pharmaceutical composition according to claim 1, wherein the formulation base contains water soluble additives suitable for incorporation in a dosage form intended for oral administration.

9. A process for the preparation of the pharmaceutical composition according to claim 1, which is characterized in that an aqueous dispersion of nanoparticles containing a) the active agent to be solubilized and b) the solubilizing agent, which is suitable for the formation of an aqueous dispersion of nanoparticles, is formed; and the dispersion is processed further under the optional addition of pharmaceutically acceptable additives c), which are suitable for the incorporation in a dosage form for the oral administration.

10. A process according to claim 9, characterized in that the aqueous dispersion of nanoparticles is processed further to a lyophilisate.

11. A process according to claim 9, characterized in that the aqueous dispersion of nanoparticles is filled into starch, hard gelatin or soft gelatin capsules.